A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)

Summary

The purpose of this study is to investigate the use of benralizumab is effective in the treatment of chronic spontaneous urticaria (CSU) who are symptomatic despite the use of antihistamines.

Timeline

Start

2020-10-27

Primary completion

2022-10-13

Completion

2023-03-28

Outcome

Missed primary endpoint

Stopped: “Study did not meet primary endpoint”

registry analysis (superiority test); Benralizumab 30 mg vs Placebo; p = 0.3824; LS mean difference -1.01 (95% CI -3.28 to 1.26) NCT04612725 ↗

registry analysis (superiority test); Benralizumab 60 mg vs Placebo; p = 0.1244; LS mean difference -1.79 (95% CI -4.09 to 0.50) NCT04612725 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Benralizumab	Monoclonal antibody	—	—

Indications